Moderna (MRNA) Capital Leases (2017 - 2026)

Moderna (MRNA) has 10 years of Capital Leases data on file, last reported at $13.0 million in Q1 2026.

• On a quarterly basis, Capital Leases fell 62.86% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 62.86% decrease from a year earlier, with the FY2025 full-year figure at $20.0 million, down 48.72% from the prior year.
• Capital Leases for Q1 2026 stood at $13.0 million, down from $20.0 million in the prior quarter.
• Over the last five years, Capital Leases for MRNA reached as high as $922.0 million in Q3 2022 and fell as low as $13.0 million in Q1 2026.
• Historically, Capital Leases has averaged $463.9 million across 5 years, with a median of $575.0 million in 2023.
• Across the five-year window, Capital Leases jumped 368.12% in 2022 and plunged 95.84% in 2025, its largest moves.
• Year by year, Capital Leases stood at $912.0 million in 2022, then sank by 36.95% to $575.0 million in 2023, then sank by 93.22% to $39.0 million in 2024, then tumbled by 48.72% to $20.0 million in 2025, then plunged by 35.0% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Capital Leases figures were $13.0 million in Q1 2026, $20.0 million in Q4 2025, and $26.0 million in Q3 2025.